GSK Pays $10.6 Billion for Nuvalent to Re-Enter Oncology

GSK agreed last week to acquire Boston-based Nuvalent for $10.6 billion in cash, the British drugmaker's biggest deal on record and its clearest signal yet that new CEO Luke Miels intends to rebuild the oncology franchise the company sold off a decade ago.

Under terms disclosed in a filing reviewed by the SEC, GSK will pay $124 per share, a 40% premium to Nuvalent's last closing price and a 26% premium to its 30-day volume-weighted average price. Net of cash acquired, the out-of-pocket investment comes to $9.4 billion, funded through new and existing debt facilities plus cash on hand. GSK said the deal is expected to close in the third quarter of 2026, pending regulatory and tender-offer conditions.

The price tag buys three lung cancer programs in a single transaction. The two lead assets, zidesamtinib and neladalkib, are next-generation inhibitors targeting the ROS1 and ALK gene alterations that drive non-small cell lung cancer. Both carry FDA Breakthrough Therapy and Orphan Drug designations, according to Nuvalent's SEC filings. PDUFA action dates are September 18 and November 27, 2026, respectively, meaning GSK could have two new approved products on shelves before year-end if regulators stick to schedule. A third asset, NVL-330, is a Phase I HER2 inhibitor still in early-stage trials.

GSK framed the deal as consistent with its stated strategy of acquiring programs with clinically validated targets that address tolerability or efficacy gaps versus current standard-of-care, according to its press release. The clinical pitch on both lead drugs centers on improved CNS penetration, reduced metabolic side effects, and broader coverage of resistance mutations that blunt existing ALK and ROS1 inhibitors over time.

The financial math is front-loaded with dilution. GSK guided for low single-digit core EPS drag through 2028, with revenue and operating profit contributions beginning in 2027 and core EPS accretion not arriving until 2029, per the SEC filing. Management said there is no change to its 2026 full-year guidance for 7-9% core operating profit and core EPS growth, a figure the market will watch closely given the debt load being added.

The strategic logic is harder to argue with on paper. GSK exited oncology in 2015 via a $16 billion asset swap with Novartis. Miels, who took the chief executive role at the start of 2026, has consistently pointed to cancer as a priority rebuild area, and the Nuvalent pipeline gives him two assets with near-term binary catalysts rather than years of phase II guesswork. The deal also addresses a structural revenue problem: analysts estimate GSK's total drug sales this year at roughly £34 billion, but the HIV franchise anchored by dolutegravir faces patent expiry later this decade, and the company needs durable replacement revenue.

Intelligence on the week's deal flow, reported by Intellizence, put the GSK transaction as the largest single announcement in the seven days ending June 14, with the five biggest deals of that stretch totaling more than $20 billion in disclosed value.

Whether the $124 price holds up to scrutiny depends almost entirely on what FDA does with the two PDUFA dates this fall. GSK is, in effect, paying a takeover premium for regulatory outcomes that haven't happened yet. That's not unusual in late-stage oncology M&A, but it does mean the accretion timeline management laid out is contingent on approvals GSK doesn't control.

Sources cited:
- Nuvalent, Inc. Form 8-K (SEC filing) (https://www.sec.gov/Archives/edgar/data/0001861560/000119312526262950/d137459dex991.htm)
- GSK Press Release via gsk.com (https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/)
- Pharmaceutical Technology (https://www.pharmtech.com/view/gsk-acquires-nuvalent-for-10-billion-in-lung-cancer-push)
- PharmExec (https://www.pharmexec.com/view/gsk-enters-10-billion-agreement-acquire-nuvalent-inc)
- Intellizence M&A Deals Tracker (https://intellizence.com/insights/merger-and-acquisition/major-ma-deals-pharma-automotive-food-ingredients-biotech-and-medtech-led-the-weeks-biggest-announcements/)
- IndexBox / Reuters reporting (https://www.indexbox.io/blog/gsk-announces-record-106-billion-acquisition-of-nuvalent-to-rebuild-oncology-portfolio/)